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The association of elevated lipoprotein (a) (Lp(a)) with an increased risk for coronary events is clearly established. This increased risk
may in part be due to the activation of monocytes as major cells involved in atherogenesis. High concentrations of plasma Lp(a) were shown
to influence the gene expression of human blood monocytes and in the present study we demonstrate a reduced abundance of the lysosomal
acid lipase (LAL) mRNA in monocytes of patients with coronary disease and selective Lp(a) hyperlipidemia. This is also supported by in
vitro studies where purified Lp(a) but not low-density lipoprotein (LDL) was shown to downregulate mRNA levels of the LAL in control
monocytes. A correlation of Lp(a) serum levels and the proinflammatory cytokine IL-6 was recently also described. Therefore, we
investigated whether Lp(a) is capable to enhance the release of this acute phase cytokine from human blood monocytes. Purified Lp(a) led to
an increased secretion of IL-6, but not TNF-a arguing against a general activation of these cells. The association of reduced LAL activity
with the premature development of coronary artery disease has been demonstrated in patients with hypercholesterolemia, and in the present
study we show for the first time that LAL expression is suppressed in monocytes from patients with Lp(a) hyperlipidemia and by purified
Lp(a). In addition, increased levels of IL-6 also predict future cardiovascular events and IL-6 secretion was also induced by purified Lp(a).D 2003 Elsevier B.V. All rights reserved.Keywords: Lipoprotein (a); Lysosomal acid lipase; Interleukin-6; Blood monocyte; Atherogenesis1. Introduction
Lipoprotein (a) (Lp(a)) is a low-density lipoprotein
(LDL) particle where apoB100 is linked by a disulfide bond
to apolipoprotein (a) (apo(a)). Lp(a) has been recognized as
a risk factor for atherosclerosis [1,2] and the structural
similarity of apo(a) with plasminogen may explain some
of the atherogenic features of this lipoprotein [3]. Lp(a)
exerts different effects on cells involved in the development
of atherosclerotic lesions. First, Lp(a) increases the synthesis
of plasminogen activator inhibitor-1 (PAI-1), the production
of vascular adhesion molecule 1 (VCAM-1) and E-selectin
in endothelial cells [4]. Second, the proliferation of vascular
smooth muscle cells (VSMC) is enhanced by the reduced0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/S0167-4889(03)00083-1
* Corresponding author. Tel.: +49-941-944-6201; fax: +49-941-944-
6202.
E-mail address: gerd.schmitz@klinik.uni-regensburg.de (G. Schmitz).activation of plasminogen to plasmin, thus blocking the
proteolytic activation of transforming growth factor-beta, an
autocrine inhibitor of VSMC proliferation [5]. Third, in
THP-1 macrophages, the secretion of interleukin-8 was
found increased [6].
Whereas most of the published studies focus on the
influence of elevated Lp(a) on the generation of the athero-
sclerotic plaque, the interaction of high Lp(a) with blood
monocytes is poorly investigated. Blood monocytes are
influenced by dyslipidemia, functionally abnormal mono-
cytes have been reported in patients with hypercholesterol-
emia [7] and more mature monocytes are described in
patients with xanthomatosis [8]. The monocyte chemoat-
tractant protein-1 receptor CCR2 on circulating monocytes
correlates with plasma LDL [9] and a significant increase of
CD40 on monocytes of patients with moderate hypercho-
lesterolemia has been published [10]. The expression of the
variant activation antigen CD45RA by peripheral blood
monocytes showed a positive correlation to plasma levels
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cently, we identified differentially expressed genes in mono-
cytes from a patient with isolated Lp(a) hyperlipidemia
compared to control monocytes using a microarray. Subse-
quent confirmation of these candidates in patients suffering
from coronary heart disease (CHD) and high Lp(a), in
healthy donors with high Lp(a) and controls with low
Lp(a) revealed an induction of plasminogen activator inhib-
itor type 2 (PAI-2) in monocytes from male, but not from
female individuals with high Lp(a). PAI-1 mRNAwas found
suppressed only in the patients’ monocytes and not in
healthy probands with high Lp(a) levels [12]. However,
most of the identified candidate genes resulted from inter-
individual differences in the gene expression of the two
donors and were not related to Lp(a) hyperlipidemia.
Therefore, the gene expression in monocytes of a second
patient with high Lp(a) as the only obvious risk factor for
premature atherosclerosis [13] was analyzed. By this ap-
proach, the probability to detect disease-related genes and
to distinguish them from interindividual variances in gene
expression is markedly increased. Besides the genes al-
ready described, the expression of the lysosomal acid lipase
(LAL) was found suppressed in the patients’ cells. Further-
more, purified Lp(a) also downregulates LAL mRNA in
control monocytes and induces an enhanced release of IL-
6, a chemokine with pro-inflammatory properties. There-
fore, we conclude that these events may be relevant to the
process of premature atherosclerosis in probands with high
Lp(a).2. Materials and methods
2.1. Patients and probands with elevated Lp(a)
Data of the patients with a history of myocardial infarc-
tion (P1, P2, P3, P4) [13] and healthy blood donors with
elevated Lp(a) (L1 to L10) are listed in Table 1. Lp(a) was
determined by a nephelometric test (Immuno AG, Vienna,
Austria). Healthy blood donors with normal lipid status and
Lp(a) plasma levels of less than 5 mg/dl were used as
controls (C1 to C20). The isolation of blood monocytes was
approved by the Medical Ethics Committee of the Univer-
sity Hospital of Regensburg, Germany.Table 1




Patients (P1 to P4) 4 113.2F 21.9
Healthy probands with high
Lp(a) (L1 to L10)
10 112.2F 27.3
Controls (C1 to C20) 20 < 5
P1 to P4 are patients with Lp(a) hyperlipidemia and a history of myocardial infarc
with high Lp(a) levels and C1 to C20 healthy controls with Lp(a) of less than 5The apo(a) isoforms were determined with sodium
dodecyl sulfate-polyacrylamide gel electrophoresis followed
by immunoblotting as previously described with the mono-
clonal antibody 1A2 [14]. The number of apoA-IV kringles
is given in brackets and is as follows: P1 (15/20), P2 (14/
32), P3 (19/30) and P4 (15/20). Lp(a) for the incubation of
monocytes was isolated from healthy donors with high
Lp(a). The number of apoA-IV kringles is: L1 (17/?), L2
(20/37), L3 (17/19) and L4 (18/28). All of the patients and
probands had at least one small apo(a) isoform defined as 17
to 22 kringle IV repeats [15], which is in accordance with
the higher Lp(a) concentrations.
2.2. Culture media and reagents
RPMI medium was from Gibco BRL (Karlsruhe, Ger-
many). LPS, E. coli serotype O55:B5, and other laboratory
reagents and chemicals were purchased from Sigma Chem-
ical (Deisenhofen, Germany) unless noted otherwise. Ny-
lon membranes (Genescreen) for Northern blotting were
from NEN Life Science (Boston, MA) and [a32P]dCTP
was from Amersham Pharmacia Biotech (Braunschweig,
Germany). Oligonucleotides were synthesized by MWG
(Ebersberg, Germany). IL-6, IL-6 ELISA and TNF-a
ELISA was from R&D Systems (Wiesbaden-Nordenstadt,
Germany).
2.3. Isolation and culture of monocytes
Peripheral blood monocytes from healthy blood donors
with elevated Lp(a), patients with Lp(a) hyperlipidemia and
controls were isolated by leukapheresis followed by coun-
terflow elutriation. Fractions containing >95% monocytes
were pooled and cultured on plastic Petri dishes (1106
cells/ml) in RPMI medium with 20% autologous serum for
the indicated times.
2.4. Isolation of LDL and Lp(a)
LDL and Lp(a) lipoproteins were purified from citrated
plasma of healthy donors as described by Kostner et al. [16].
Endotoxin in the isolated lipoproteins was determined by an
assay from Sigma and was less than 0.01 ng/ml in the
culture medium.LDL (mg/dl) HDL (mg/dl) Age of the
probands
138.1F10.7 39.6F 7.6 48.3F 6.4
139.4F 36.3 72.5F 21.2 34.6F 17.3
103.4F 16.5 50.4F 18.4 35.2F 13.1
tion with the last event at least 7 years ago. L1 to L10 are healthy controls
mg/dl.
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Total cellular RNA from elutriation-purified monocytes
was isolated by the guanidine isothiocyanate–cesium chlo-
ride technique [17]. Ten micrograms of total RNA was
separated through a 1.2% agarose gel containing 6% form-
aldehyde and blotted onto nylon membranes. After cross-
linking with UV-irradiation (Stratalinker model 1800,
Stratagene, La Jolla, CA), the membranes were hybridized
with a cDNA probe generated by RT-PCR. The LAL probe
was amplified using the primers LAC1 (5V-CCCGGCAG-
GACAGCTCCAGA-3V) and LAC2 (5V-GTGTGACA-
CAGCTCAAGTCCA GCTT-3V) and the IL-6 probe with
IL6uni (5V-ATGAACTCCTTCTCCACAAGCGC-3V) and
IL6rev (5V-GAAGAGCCCTCAGGC TGGACTG-3V). The
membranes were stripped and subsequently hybridized with
a human GAPDH probe (Clontech, Palo Alto, CA). The
probes were radiolabeled with [a-32P]dCTP using the
Prime-It II Kit from Stratagene (Amsterdam Zuidoost,
Netherlands). Hybridization and washing conditions were
performed as recommended by the manufacturer of the
membrane.
2.6. Microarray hybridization
mRNA was purified from total RNA by oligodT beads
(Roche, Penzberg, Germany). Hybridization, signal detec-
tion and data analysis was performed by Incyte Genomics
(for detailed information see http://www.incyte.com).
Two hundred nanograms of mRNA isolated from mono-
cytes of patient 1 or patient 2 and control 1 were indepen-
dently reverse-transcribed using Cy5- or Cy3-labeled
nucleotides, respectively, mixed and simultaneously hybrid-
ized to the UniGEMk V 2.0 microarray with 8556 human
cDNAs spotted. The array was rinsed and scanned for the
two fluorescent dyes independently. Data were analyzed
using GemToolsk software and were calculated as expres-
sion ratios of patient to control mRNA.
2.7. Monitoring of gene expression by real-time RT-PCR
Two micrograms of total RNA were reverse-transcribed
using the Promega Reverse Transcription System in a
volume of 40 Al. Two microliters of cDNA were subse-
quently amplified in glass capillaries (LightCycler) using
PCR primers specific for GAPDH and LAL. The reaction
conditions were as follows: 2 Al cDNA, 2 Al 10 Light-
Cycler-Fast Start DNA Master SYBR Green I (Roche
Diagnostics GmbH, Mannheim, Germany), 2.4 Al MgCl2
(25 mM), 1 Al of each primer (5 pmol/Al), in a total volume
of 20 Al. The primers for GAPDH were: GAPDHuni: 5V-
TTGGTATCGTGGAAGGACTCA, GAPDHrev 5V-TGTC-
ATCATATTTGGCAGGTTT.
The primers for LAL were: LAC-385uni: 5V-GTGG-
ATGGGCAACAGCAGAGG, LAC-803rev: 5V-CCTTCAG-
TATGACATGAGTGC.Amplification in the LightCycler capillaries was for 45
(40) cycles for LAL (GAPDH) with initial incubation of 10
min at 95 jC for activation of TaqPolymerase. Cycling
parameters were 10 s at 95 jC, 10 s 55 jC (60 jC for
GAPDH) and 15 s at 72 jC (5 s for GAPDH). Fluorescence
was monitored at 82 jC (85 jC for GAPDH). The second
derivative method was used for quantification with the
LightCycler software.
2.8. Generation of standard curves
For quantification of the results obtained by real-time
PCR, we used the standard curve method. For this
purpose, a stock of total RNA from control monocytes
was serially diluted. A standard curve with 50, 25, 12.5,
6.25 ng total RNA was generated for LAL and
GAPDH. The standard curves were used to determine
the relative expression of LAL and GAPDH mRNA in
each sample.
2.9. ELISA
Ten million cells were incubated for 24 h in RPMI,
20% autologous serum and LDL or Lp(a) as indicated.
Ten microliters of the supernatant were used for IL-6
or TNF-a protein determinations. The ELISA was
performed as recommended by the distributor (R&D
Systems).3. Results
3.1. Identification of differentially expressed genes in
monocytes from patients with isolated Lp(a) hyperlipidemia
using a microarray
Recently, we have shown that by comparing the gene
expression patterns of monocytes isolated from a patient
with high Lp(a) (P1) and monocytes from a control
individual with low Lp(a) (C1) using a microarray, most
of the genes identified to be differentially expressed are the
result of interindividual differences between unrelated
donors and were not associated with high Lp(a) serum
levels [12]. Therefore, an additional hybridization experi-
ment with mRNA purified from monocytes of a second
patient with high Lp(a) was performed. Genes that were
similarly up- or downregulated in the two mRNA samples
of the patients were PAI-2, PAI-1, defensins [12] and LAL.
In the present study, we focus on the regulation of the
LAL gene. LAL mRNA was suppressed 2.8-fold in mono-
cytes isolated from patient 1 (P1) and 4.2-fold in mono-
cytes from patient 2 (P2) in comparison to the control
(C1). The mRNAs of additional lysosomal genes like acid
sphingomyelinase and lysosomal cysteine proteases were
not differentially expressed in patients versus control
monocytes.
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elevated Lp(a) and controls
Further analysis of LAL mRNA by Northern blot in
monocytes from Lp(a) patients (P1, P2), healthy probands
with high Lp(a) (L1, L2) and six controls with low Lp(a)
confirmed that LAL mRNA is downregulated in Lp(a)
patients (below the sensitivity of a Northern blot) (Fig.
1A). The expression of LAL mRNA in monocytes of the
healthy probands L1 and L2 with serum concentrations of
Lp(a) similar to that of the patients is like in the controls
with low Lp(a) (C1 to C6). Because of the high variability
of LAL mRNA expression in the control group, we deter-
mined LAL mRNA by real-time RT-PCR in the Light-
Cycler. RNA isolated from the monocytes of 20 different
control individuals, of 10 healthy individuals with high
Lp(a) and of 4 patients (P1 to P4) was analyzed. Light-
Cycler analysis was performed twice with a standard devi-
ation of lower than 0.2 (not indicated here). The relative
expression of LAL and GAPDH were determined using the
standard curves and division of LAL expression by the
GAPDH values was done for normalization. The relative
normalized value for the LAL mRNA in the control group
was 6.9F 8.7, for healthy probands with high Lp(a)
3.4F 1.6 and 1.4F 0.7 for the patients. This indicates a
2-fold reduction of LAL mRNA in healthy probands withFig. 1. Analysis of LAL expression in various individuals and in monocytes
incubated with Lp(a) in vitro. (A) Elutriation-purified monocytes from
patients with isolated Lp(a) hyperlipidemia (P1, P2), healthy controls with
elevated Lp(a) (L1, L2) and six controls with low Lp(a) (C1 to C6) were
incubated in 20% autologous serum for 24 h. RNA was isolated and 10 Ag
of total RNAwas used in a Northern blot to analyze the expression of LAL.
Equal RNA loading was confirmed by reprobing the blot with GAPDH. (B)
Elutriation-purified monocytes from a donor with low Lp(a) were incubated
with purified LDL (100 and 60 Ag/ml), and with purified Lp(a) (100 and 60
Ag/ml) in 20% autologous serum or in 20% serum alone (control) for 24 h.
Total RNA was isolated and the expression of LAL and GAPDH was
analyzed.high Lp(a) and a 4.9-fold reduction in patients with high
Lp(a) when compared to the control group.
Due to the high variation of LAL mRNA levels in the
control group, these data are not statistically significant.
Nevertheless, the values indicate a downregulation of LAL
mRNA in healthy probands with high Lp(a) and suppression
of LAL mRNA in the patients.
3.3. Regulation of LAL mRNA by purified Lp(a)
To further support the observation that Lp(a) regulates
LAL expression, we incubated monocytes isolated from
two healthy probands with purified Lp(a) or LDL for 24 h.
Lp(a) and LDL were isolated from the plasma of healthy
donors L1 to L4 and lipoproteins from the identical donor
were used in one experiment. Northern blot analysis
revealed a downregulation of LAL mRNA when the cells
were incubated with 100 Ag/ml Lp(a) for 24 h. LAL
mRNA was suppressed 7.1F 2.1-fold as determined by
LightCycler analysis of the corresponding mRNAs from
two donors. Lp(a) (60 Ag/ml) added for 24 h downregulate
LAL mRNA 2.5F 1.4-fold (Fig. 1B). LDL did not influ-
ence LAL mRNA levels. A similar result was seen in the
monocytic cell line THP-1 incubated with PMA to induce
differentiation and 100 Ag/ml Lp(a) or LDL for 24 h (not
shown). LAL mRNA was downregulated in THP-1 cells
treated with 100 Ag/ml purified Lp(a) by a factor of
3.7F 1.3 whereas LDL did not modulate LAL expression
in THP-1 cells.
The downregulation of LAL mRNA is only detected in
monocytes cultivated in the presence of serum. Monocytes
in serum-free medium supplemented with M-CSF and
incubated with purified Lp(a) show no altered LAL mRNA
expression, indicating that Lp(a) mediated regulation of
LAL mRNA depends on a serum factor present in human
serum.
3.4. Regulation of LAL mRNA by lipopolysaccharide (LPS)
Purified Lp(a) influences the gene expression of PAI-2 in
a proinflammatory way, namely PAI-2 mRNA is induced by
Lp(a) [12] and LPS [18]. However, to our knowledge, the
regulation of LAL mRNA expression in human blood
monocytes upon LPS treatment is not investigated. To see
whether the suppression of LAL mRNA also resembles a
proinflammatory response monocytes from two controls
were incubated with different amounts of LPS. LPS, in 10
and 100 pg/ml concentrations, had no influence on LAL
mRNA expression, but a significant downregulation is
induced by 1, 10 and 100 ng/ml LPS in the presence of
serum (Fig. 2). LightCycler expression analysis revealed a
5.3F 1.2-fold downregulation of LAL mRNA for donor 1
for 1, 10 and 100 ng/ml LPS and 12.8F 1.8-fold suppres-
sion for donor 2. Therefore, 1 ng/ml LPS is sufficient to
downregulate LAL mRNA in human blood monocytes and
higher amounts of LPS have no additional effect on the
Fig. 3. Analysis of IL-6 expression in various individuals and in monocytes
incubated with Lp(a) in vitro. (A) Elutriation-purified monocytes were
incubated in 20% autologous serum for 24 h. Secreted IL-6 was determined
in the supernatant of monocytes from four probands with low Lp(a)
incubated with serum alone, with 100 Ag/ml LDL or with 100 Ag/ml
purified Lp(a). IL-6 is given as pg/ml. Mean values obtained from four
independent determinationsF S.D. are shown. Significance was determined
using t-test (*P < 0.001). (B) Elutriation-purified monocytes from patients
with isolated Lp(a) hyperlipidemia (P1, P2), healthy controls with elevated
Lp(a) (L1, L2) and six controls with low Lp(a) (C1 to C6) were incubated in
20% autologous serum for 24 h. RNAwas isolated and 10 Ag of total RNA
was used in Northern blots to analyze the expression of IL-6. (C)
Elutriation-purified monocytes from a donor with low Lp(a) were incubated
with purified LDL (100 and 60 Ag/ml) or with purified Lp(a) (100 and 60
Ag/ml) in 20% autologous serum or in 20% serum alone (control) for 24 h.
Total RNA was isolated and the expression of IL-6 was analyzed.
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is suppressed in human monocytes by Lp(a) and LPS.
3.5. Lp(a) induces the secretion of IL-6
IL-6 was found to stimulate Lp(a) production in hepato-
cytes [19] and furthermore Lp(a) concentrations are related
to serum IL-6 levels in some studies [20,21]. Therefore, it
might well be that Lp(a) enhances the secretion of IL-6. We
determined IL-6 and TNF-a in the supernatant of human
monocytes incubated with serum alone, with 100 Ag/ml
LDL or 100 Ag/ml Lp(a) for 24 h. Whereas TNF-a levels
were unchanged (not shown), IL-6 secretion was signifi-
cantly increased in cells treated with Lp(a) (Fig. 3A). IL-6
was 175.6F 35 pg/ml in the culture medium of monocytes
cultivated in the presence of serum and 97.6F 83 pg/ml
with LDL. Although LDL seems to downregulate IL-6
secretion, this difference was not significant using t-test.
In the presence of Lp(a), monocytes released 687F 114 pg/
ml IL-6, which is a nearly 4-fold and significant induction of
IL-6 (P < 0.001).
In addition, IL-6 levels in the serum of patients with
isolated Lp(a) hyperlipidemia (1.85F 0.2 pg/ml), in healthy
probands with high Lp(a) (1.7F 0.38 pg/ml) and in controls
with low Lp(a) (1.5F 0.36 pg/ml), were determined by
ELISA. Although IL-6 levels seem to be slightly increased
in Lp(a) patients and healthy probands with high Lp(a)
compared to controls, this difference was not significant.
The microarray data revealed no significant differences
in the mRNA levels of IL-6 and TNF-a in monocytes
isolated from P1, P2 and C1. Northern blot analysis with
a IL-6-specific probe was performed. IL-6 mRNA is easily
detectable by this method and the variance in IL-6 mRNA in
monocytes from different donors is low (Fig. 3B). The IL-6
mRNA expression was also not induced in monocytes
treated with purified Lp(a) in vitro (Fig. 3C), indicating a
posttranscriptional regulation. We further investigated
whether IL-6 may mediate LAL suppression in monocytes.Fig. 2. Northern blot analysis of LAL mRNA in monocytes incubated with
LPS. Elutriation-purified monocytes from two donors were incubated with
LPS (10 pg/ml, 100 pg/ml, 1 ng/ml, 10 ng/ml and 100 ng/ml) or in 10%
autologous serum alone for 24 h. Expression of LAL mRNA and GAPDH
mRNA (donor 1) was analyzed.Monocytes were incubated with 10 ng/ml IL-6 for 24 h or
LPS as control. Whereas LPS downregulates LAL mRNA,
IL-6 did not change LAL mRNA levels (not shown),
indicating that induced IL-6 secretion does not mediate
the suppression of LAL mRNA.4. Discussion
Elevated plasma Lp(a) is a risk factor for premature
cardiovascular disease [1,2]. Lp(a) modulates the gene
expression of cells involved in the formation of atheroscle-
rotic lesions namely endothelial cells [4], smooth muscle
cells [5] and macrophages [6]. We recently described that
Lp(a) also alters the gene expression of human blood
monocytes with PAI-2 being induced and PAI-1 secretion
being diminished [12]. In this study, we focus on the
reduced expression of LAL mRNA identified in the mono-
cytes of two patients with high Lp(a) and cardiovascular
disease by microarray hybridization. This was also con-
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tive PCR, the expression of LAL mRNA was studied in the
monocytes of 4 patients with high Lp(a), 10 healthy pro-
bands with high Lp(a) and 20 controls. We found a 2-fold
reduction of LAL mRNA in monocytes from healthy pro-
bands with high Lp(a) and a 4.9-fold reduction in patients
with high Lp(a) when compared to the control group. LAL
mRNA expression is highly variable within the controls and
to further support our observation in vitro studies were
performed. Monocytes were incubated with purified Lp(a)
and LAL mRNA was found suppressed in these cells
whereas the incubation with LDL as a control had no
influence on LAL mRNA levels. This indicates that the
LDL moiety of Lp(a) does not suppress LAL expression and
even oxidized LDL was demonstrated not to impair lyso-
somal hydrolysis of cholesteryl esters in macrophages [22].
LAL contributes to the prevention of lipid overload in the
liver, spleen and macrophages [23], and LAL activity is
reduced in cholesteryl ester storage disease (CESD) patients
[24,25]. This disorder is characterized by high LDL choles-
terol and an accumulation of cholesteryl esters and trigly-
cerides in most tissues and early atherosclerosis [26]. The
severity of the disease correlates with the residual LAL
activity [25,27]. Plasma cholesterol and triglyceride levels
are not elevated in patients with high Lp(a) [28] but they are
in patients with reduced LAL activity [26]. Therefore, we
suggest that LAL activity in the liver as a main organ
determining plasma LDL and HDL levels is not significant-
ly altered. Lipid overload of macrophages is unlikely to
change plasma LDL but may promote the generation of
atherosclerotic lesions [29].
Atherosclerosis is an inflammatory disease [30] and the
monocyte response to atherogenic stimuli and to proinflam-
matory mediators like LPS is often similar. Indeed, LPS, the
most potent inflammatory stimulus, also downregulated
LAL mRNA expression in human blood monocytes.
The proinflammatory cytokine IL-6 stimulates the secre-
tion of apo(a) from hepatocytes [19] and a correlation of
Lp(a) levels and IL-6 in patients with high apo(a) isoforms
and monoclonal gammopathy was recently reported [21].
Therefore, we investigated whether Lp(a) may induce IL-6
secretion in human blood monocytes. IL-6 release was
significantly enhanced in the cells incubated with purified
Lp(a) in vitro whereas TNF-a release was not induced by
this atherogenic lipoprotein. IL-6 levels in the serum of
patients with isolated Lp(a) hyperlipidemia, in healthy
probands with high Lp(a) and in controls with low Lp(a)
were determined. Although IL-6 levels slightly declined
from Lp(a) patients to healthy Lp(a) probands to controls,
the difference was not significant. Baggio et al. [20]
published similar data. In their study, IL-6 levels did not
correlate to high Lp(a) with the exception of the centenar-
ians. IL-6 concentrations were significantly higher in cen-
tenarians with high Lp(a) when compared to centenarians
with low Lp(a). Similarly, PAI-1 secretion is reduced in
monocytes from patients with high Lp(a) and also in in vitrostudies [12]. An inverse relation of Lp(a) and PAI-1 was
demonstrated in the serum of type 2 diabetic patients [31],
whereas PAI-1 was not reduced in the serum of patients with
high Lp(a) not suffering from type 2 diabetes.
Lp(a) stimulates the secretion of IL-6, an acute phase
cytokine inducing apo(a) production in hepatocytes and
furthermore downregulates LAL in monocytes from patients
with isolated Lp(a) hyperlipidemia and in monocytes incu-
bated with Lp(a) in vitro. Therefore, high Lp(a) may
contribute to the premature development of severe athero-
sclerosis by impairing lysosomal cholesterylester hydrolysis
and enhancing the secretion of the multifunctional proin-
flammatory cytokine IL-6.Acknowledgements
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